Cignas 2026 commercial formulary includes six GLP-1 medications: Wegovy (semaglutide for obesity and CVD), Zepbound (tirzepatide for obesity and OSA), Ozempic (semaglutide for type 2 diabetes), Mounjaro (tirzepatide for type 2 diabetes), Saxenda (liraglutide for obesity), and Rybelsus (oral semaglutide for type 2 diabetes)
Contact your GP if cravings accompany hypoglycaemia symptoms (trembling, sweating, confusion), interfere with dietary management or blood glucose control, or occur alongside concerning symptoms such as persistent abdominal pain or unexplained weight gain
Follow the instructions provided with the medication for proper injection technique
In addition, it also slow the stomach emptying and reduces the feeling of hunger
The medication works by mimicking the action of GLP-1, a naturally occurring hormone in the body that regulates appetite and food intake